(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,2S)-VU0155041 is the cis regioisomer of VU0155041 and a partial agonist of mGluR4.

(1R,3S)-THCCA-Asn (4j) is a selective inhibitor of thrombin (IC50: 0.07-0.14 μM) with anti-thrombotic effects.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid is a potential SSTR4 agonist.

(1R,6R,9R)-6,9,11-Trihydroxy-4,7-megastigmadien-3-one 11-O-glucoside is a natural product for research related to life sciences. The catalog number is TN6201 and the CAS number is 289914-68-7.

kappa-Bifenthrin is a pyrethroid insecticide.

(1R)-α-Pinene is a natural product for research related to life sciences. The catalog number is TN2469 and the CAS number is 7785-70-8.

(1S,2R,4S,9R,10R,14S,15S,17S)-9-(furan-3-yl)-1-hydroxy-15-[(1R)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,?.0?,13.0?,1?]octadecan-17-yl 2-methylpropanoate is a useful organic compound for research related to life sciences and the catalog number is T130049.

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, with promising implications for Alzheimer’s disease (AD) therapy [1]. This compound effectively addresses the metabolic liability associated with carbonyl reduction, while demonstrating potent inhibition of calpain 1 with an IC50 value of 395 nM [2].

(1S,2R)-Globalagliatin 是一种高效的葡萄糖激酶 (GK) 激活剂，可用于研究 3 型糖尿病。

(1S,2R)-Globalagliatin 是一种高效的葡萄糖激酶 (GK) 激活剂，可用于研究 3 型糖尿病。

(1S,2R)-Globalagliatin 是一种高效的葡萄糖激酶 (GK) 激活剂，可用于研究 3 型糖尿病。

(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1 .

(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1 .

(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1 .

(1S,2S,3R)-DT-061 is an enantiomer of DT-061 which is an orally bioavailable activator of PP2A.

(1S,2S,3R)-DT-061 is an enantiomer of DT-061 which is an orally bioavailable activator of PP2A.

(1S,2S,3R)-DT-061 is an enantiomer of DT-061 which is an orally bioavailable activator of PP2A.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.